Takeda Pharmaceutical Co Ltd

Takeda’s Phase‑III results for oral psoriasis drug zasocitinib show rapid, durable remission and strong safety, positioning it to rival injectable biologics and drive future growth.

Takeda Pharmaceutical’s 9‑month profit jump shows strong growth in oncology, GI, CNS drugs, boosting its Tokyo shares and investor confidence.

Takeda Pharmaceutical Co Ltd continues to demonstrate steady growth and stability in its stock performance, driven by its focus on cutting-edge research and development in key therapeutic areas.

Takeda Pharmaceutical Co Ltd continues to make significant strides in its core therapeutic areas, with a strong market position and robust financial health, positioning it for future growth and innovation.

Takeda Pharmaceutical Co Ltd reports mixed quarterly performance, but its strong market position, robust pipeline, and strategic initiatives suggest a resilient future.